INmune Bio (INMB) 10-Q2024 Q3 Quarterly report

Filed: 31 Oct 24, 4:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: academic, Agency, Alpha, announced, Anthony, attempting, biopharma, biotech, blocking, Bullosa, burn, call, capability, CDR, cellular, cGMP, children, cord, CORDstrom, CSO, disfiguring, dispute, EB, EEG, erroneously, fatal, Great, half, Hospital, human, hypoxic, invoiced, lapsed, low, mesenchymal, mild, multicenter, Nolan, opportunistic, Ormond, passage, path, permanent, Poland, power, properly, quality, RBC, reference, replaced, respiration, screening, segment, single, site, skin, sponsored, stem, stromal, TAM, threatened, umbilical

Removed: asserted, brought, enforcement, guarantee, likelihood, MRI, MSC, offered, predict, quantifying, recover, recovery, remain, set, statutory, violation, white

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated INMB transcripts

INMB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of INmune Bio Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Raymond J. Tesi, Chief Executive Officer of the Company, certify to my knowledge and in my capacity, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 31, 2024

/s/ Raymond J. Tesi
Raymond J. Tesi
Chief Executive Officer
(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.